Effects of resveratrol supplementation on plasma lipids: A systematic review and meta-analysis of randomized controlled trials

Nutrition Reviews

Volumn 71, Issue 12, 2013, Pages 822-835

  Sahebkar, Amirhossein ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Coronary heart disease; Dyslipidemia; Grape; HDL cholesterol; LDL cholesterol; Red wine

Indexed keywords

C REACTIVE PROTEIN; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESVERATROL; TRIACYLGLYCEROL;

ARTICLE; CARDIOVASCULAR RISK; CHEMICAL STRUCTURE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET SUPPLEMENTATION; HEART PROTECTION; HUMAN; HYPOLIPEMIA; LIPID BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

VITACEAE;

CORONARY HEART DISEASE; DYSLIPIDEMIA; GRAPE; HDL CHOLESTEROL; LDL CHOLESTEROL; RED WINE;

CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; HUMANS; LIPID METABOLISM; LIPIDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STILBENES; TRIGLYCERIDES;

EID: 84888862105     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/nure.12081     Document Type: Article

References (57)

1. LaRosa JC. Future cardiovascular endpoint studies: where will the research take us? Am J Cardiol. 1999;84:545-548.
2. Musunuru K. Atherogenic dyslipidemia: cardiovascular risk and dietary intervention. Lipids. 2010;45:907-914.
3. Assmann G. Dyslipidaemia and global cardiovascular risk: clinical issues. Eur Heart J Suppl. 2006;8(Suppl F):F40-F46.
4. Baigent C, Keech A, Kearney PM, etal. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278.
5. Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol. 2007;18:401-408.
6. Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8:373-418.
7. Carey VJ, Bishop L, Laranjo N, etal. Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. Am J Cardiol. 2010;106:757-763.
8. Yan AT, Yan RT, Tan M, etal. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med. 2006;119:676-683.
9. Vang O, Ahmad N, Baile CA, etal. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS ONE. 2011;6:e19881.
10. Cherniack EP, Troen BR. Resveratrol: effects on lipids and cardiovascular risk. Curr Cardiovasc Risk Rep. 2013;7:9-16.
11. Voloshyna I, Hussaini SM, Reiss AB. Resveratrol in cholesterol metabolism and atherosclerosis. J Med Food. 2012;15:763-773.
12. Xu Q, Si LY. Resveratrol role in cardiovascular and metabolic health and potential mechanisms of action. Nutr Res. 2012;32:648-658.
13. Wang H, Yang YJ, Qian HY, etal. Resveratrol in cardiovascular disease: what is known from current research? Heart Fail Rev. 2012;17:437-448.
14. Kang SS, Cuendet M, Endringer DC, etal. Synthesis and biological evaluation of a library of resveratrol analogues as inhibitors of COX-1, COX-2 and NF-κB. Bioorg Med Chem. 2009;17:1044-1054.
15. Spanier G, Xu H, Xia N, etal. Resveratrol reduces endothelial oxidative stress by modulating the gene expression of superoxide dismutase 1 (SOD1), glutathione peroxidase 1 (GPx1) and NADPH oxidase subunit (Nox4). J Physiol Pharmacol. 2009;60:111-116.
16. Timmers S, Konings E, Bilet L, etal. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011;14:612-622.
17. Zhang H, Zhang J, Ungvari Z, etal. Resveratrol improves endothelial function: role of TNFα and vascular oxidative stress. Arterioscler Thromb Vasc Biol. 2009;29:1164-1171.
18. Shen MY, Hsiao G, Liu CL, etal. Inhibitory mechanisms of resveratrol in platelet activation: pivotal roles of p38 MAPK and NO/cyclic GMP. Br J Haematol. 2007;139:475-485.
19. Berrougui H, Grenier G, Loued S, etal. A new insight into resveratrol as an atheroprotective compound: inhibition of lipid peroxidation and enhancement of cholesterol efflux. Atherosclerosis. 2009;207:420-427.
20. Park DW, Baek K, Kim JR, etal. Resveratrol inhibits foam cell formation via NADPH oxidase 1-mediated reactive oxygen species and monocyte chemotactic protein-1. Exp Mol Med. 2009;41:171-179.
21. Fukao H, Ijiri Y, Miura M, etal. Effect of trans-resveratrol on the thrombogenicity and atherogenicity in apolipoprotein E-deficient and low-density lipoprotein receptor-deficient mice. Blood Coagul Fibrinolysis. 2004;15:441-446.
22. Miura D, Miura Y, Yagasaki K. Hypolipidemic action of dietary resveratrol, a phytoalexin in grapes and red wine, in hepatoma-bearing rats. Life Sci. 2003;73:1393-1400.
23. Poulsen MM, Vestergaard PF, Clasen BF, etal. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes. 2013;62:1186-1195.
24. Militaru C, Donoiu I, Craciun A, etal. Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: effects on lipid profiles, inflammation markers, and quality of life. Nutrition. 2013;29:178-183.
25. Bhatt JK, Thomas S, Nanjan MJ. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res. 2012;32:537-541.
26. Tomé-Carneiro J, Gonzálvez M, Larrosa M, etal. Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebo-controlled, randomized trial. Mol Nutr Food Res. 2012;56:810-821.
27. Magyar K, Halmosi R, Palfi A, etal. Cardioprotection by resveratrol: a human clinical trial in patients with stable coronary artery disease. Clin Hemorheol Microcirc. 2012;50:179-187.
28. Fujitaka K, Otani H, Jo F, etal. Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment. Nutr Res. 2011;31:842-847.
29. Ghanim H, Sia CL, Abuaysheh S, etal. An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol. J Clin Endocrinol Metab. 2010;95:E1-E8.
30. Bo S, Ciccone G, Castiglione A, etal. Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial. Curr Med Chem. 2013;20:1323-1331.
31. Moher D, Liberati A, Tetzlaff J, etal. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
32. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.2. London: The Cochrane Collboration; 2009.
33. 2 gene Pro12Ala polymorphism affect nonalcoholic fatty liver disease risk? Evidence from a meta-analysis. DNA Cell Biol. 2013;32:188-198.
34. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455-463.
35. Borenstein M, Hedges L, Higgins J, etal. Comprehensive Meta-Analysis. Version 2. Englewood, NJ: Biostat; 2005.
36. Brasnyó P, Molnár GA, Mohás M, etal. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr. 2011;106:383-389.
37. Boocock DJ, Faust GE, Patel KR, etal. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev. 2007;16:1246-1252.
38. Wong RH, Howe PR, Buckley JD, etal. Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr Metab Cardiovasc Dis. 2011;21:851-856.
39. Heger A, Ferk F, Nersesyan A, etal. Intake of a resveratrol-containing dietary supplement has no impact on DNA stability in healthy subjects. Mutat Res. 2012;749:82-86.
40. Zern TL, Wood RJ, Greene C, etal. Grape polyphenols exert a cardioprotective effect in pre- and postmenopausal women by lowering plasma lipids and reducing oxidative stress. J Nutr. 2005;135:1911-1917.
41. Tomé-Carneiro J, Gonzálvez M, Larrosa M, etal. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am J Cardiol. 2012;110:356-363.
42. Pilz S, März W. Free fatty acids as a cardiovascular risk factor. Clin Chem Lab Med. 2008;46:429-434.
43. Boocock DJ, Patel KR, Faust GE, etal. Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;848:182-187.
44. Walle T, Hsieh F, DeLegge MH, etal. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004;32:1377-1382.
45. Yu C, Shin YG, Chow A, etal. Human, rat and mouse metabolism of resveratrol. Pharm Res. 2002;19:1907-1914.
46. Lagouge M, Argmann C, Gerhart-Hines Z, etal. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell. 2006;127:1109-1122.
47. Xia N, Daiber A, Habermeier A, etal. Resveratrol reverses endothelial nitric-oxide synthase uncoupling in apolipoprotein E knockout mice. J Pharmacol Exp Ther. 2010;335:149-154.
48. Frankel EN, Waterhouse AL, Kinsella JE. Inhibition of human LDL oxidation by resveratrol. Lancet. 1993;341:1103-1104.
49. Kaga S, Zhan L, Matsumoto M, etal. Resveratrol enhances neovascularization in the infarcted rat myocardium through the induction of thioredoxin-1, heme oxygenase-1 and vascular endothelial growth factor. J Mol Cell Cardiol. 2005;39:813-822.
50. Mizutani K, Ikeda K, Kawai Y, etal. Resveratrol attenuates ovariectomy-induced hypertension and bone loss in stroke-prone spontaneously hypertensive rats. J Nutr Sci Vitaminol (Tokyo). 2000;46:78-83.
51. Thandapilly SJ, Wojciechowski P, Behbahani J, etal. Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure. Am J Hypertens. 2010;23:192-196.
52. Chan V, Fenning A, Iyer A, etal. Resveratrol improves cardiovascular function in DOCA-salt hypertensive rats. Curr Pharm Biotechnol. 2011;12:429-436.
53. Goyal T, Mitra S, Khaidakov M, etal. Current concepts of the role of oxidized LDL receptors in atherosclerosis. Curr Atheroscler Rep. 2012;14:150-159.
54. Peres RC, Hirata R, Claudio SR, etal. Red dry wine modulates plasma cholesterol levels and cardiac enzymes in humans. J Pharm Nutr Sci. 2012;2:15-19.
55. Rifler JP, Lorcerie F, Durand P, etal. A moderate red wine intake improves blood lipid parameters and erythrocytes membrane fluidity in post myocardial infarct patients. Mol Nutr Food Res. 2012;56:345-351.
56. Kechagias S, Zanjani S, Gjellan S, etal. Effects of moderate red wine consumption on liver fat and blood lipids: a prospective randomized study. Ann Med. 2011;43:545-554.
57. Coimbra SR, Lage SH, Brandizzi L, etal. The action of red wine and purple grape juice on vascular reactivity is independent of plasma lipids in hypercholesterolemic patients. Braz J Med Biol Res. 2005;38:1339-1347.